8-K current report · filed Oct 13, 2026

Nurix Therapeutics, Inc. (NRIX) 8-K Current Report: October 13, 2026

Item EX-99.1Item 2.02NRIX overview

Short answer

Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on October 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026.

Nurix Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026
  • Exhibit 99.1 contains the underlying financial results and management commentary for investor review

Item EX-99.1 · Exhibit EX-99.1

  • Revenue $673.1M, including $653.2M Roche license revenue and $10.0M Sanofi milestone
  • Net income $549.8M, or $4.73 diluted EPS, versus $86.4M net loss in the prior-year quarter
  • Cash, equivalents and marketable securities $1.1B, supporting operations into the second half of 2029
  • Bexobrutideg entered registrational Phase 3 against pirtobrutinib in approximately 620 relapsed/refractory CLL/SLL patients
  • Phase 1 data showed 83.0% response rate and 22.1-month median progression-free survival, supporting the Roche partnership’s clinical rationale

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nurix Therapeutics, Inc. 8-K filings

Get the next NRIX 8-K as it lands

Follow NRIX for push alerts, or ask the research agent what this filing means.